PTC Therapeutics Says FDA Grants Fast Track Designation For PTC518 To Treat Huntington's Disease
PTC Therapeutics, Inc. (PTCT) announced Thursday that the FDA has granted Fast Track designation to the PTC518 program for the ...
Positive Outlook on PTC Therapeutics: Buy Rating Backed by Fast Track Designation and Promising Clinical Trials
Robert W. Baird analyst Joel Beatty has maintained their bullish stance on PTCT stock, giving a Buy rating on September 16. Joel Beatty has ...
PTC Therapeutics' Huntington's Treatment Gets FDA Fast Track Designation
PTC Therapeutics' treatment for Huntington's disease has received a fast track designation from U.S. health regulators. The biopharmaceutical company said Thursday that the Food and Drug ...
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
PTC Therapeutics (NASDAQ: PTCT) announced today that the FDA has granted Fast Track designation to the PTC518 program for the treatment of Huntington's disease. Fast Track designation is awarded to ...
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
PTC Therapeutics, Inc. got a dose-dependent lowering of mutant Huntingtin protein in both the blood and CSF of HD patients ...
PTC Therapeutics, Inc.: FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
PTC Therapeutics (NASDAQ: PTCT) announced today that the FDA has granted Fast Track designation to the PTC518 program for the treatment of Huntington's ...